Giant gains for Hologic; Smith & Nephew held back by DoJ probe
This article was originally published in Clinica
Cardiac ablation specialist AtriCure succeeded in narrowing its loss by 17% on the back of healthy gains in revenue. The West Chester, Ohio-based firm's top-line was boosted by a 28% increase in sales of its minimally-invasive products and a 22% increase in sales of its open-heart technology in the US. However, these gains were outweighed by research and development costs, and administrative expenses, resulting in an overall loss of $2.6m. AtriCure has narrowed its revenue outlook for 2007 to $48-48.7m and lowered its loss per share forecast to a range of 92-97 cents per share.
You may also be interested in...
The economic stress on payers caused by the pandemic will cause a setback in the development of payment approaches for regenerative therapy, Blue Cross Blue Shield executive warns.
An interim final rule posted by the CMS this week widens further a series of telehealth exemptions and lab specimen collection payment provisions it has previously issued to help providers during the COVID-19 pandemic.
The Trump administration says a COVID-19 vaccine could be available in as little as 12 months, but most experts think that is overpromising unless safety or efficacy standards are sacrificed. Many are urging pivotal studies that look at clinical outcomes, not surrogates, for US FDA approval.